期刊文献+

黑色素瘤疫苗研究进展

Tumor vaccine therapy for melanoma:review of literature
原文传递
导出
摘要 黑素瘤自发性消退现象使人关注到黑色素瘤固有的致免疫性,组织学现象及相应的临床观察亦证实体内的抗肿瘤主动免疫应答。人们利用黑素瘤作为治疗模型开展了一系列肿瘤疫苗的研究。 The phenomenon of tumor spontaneous regression of many patients with melanoma makes researchers pay much attention to the innate immunogenicity of melanoma. It's also supported by serveral manifestations of histological observation, Correspondingly, patients with Breast Medullary Carcinoma or skin Maligant Melanoma who have an infiltration of lymphocytes get better prognosis. Moreover,it's demonstrated that cytokines play an important role in such regulation of antitumor immunological reponse. All above imply that there is active anti-tumor immunological response in the body and enlighten researchers to innitiate a series of studies on tumor vaccine using the melanoma as a theraputic model. This article reviews the tumor vaccine therapy for melanoma on the advantage and disadvantage of its main types and relative clinicalo trials.
出处 《国际肿瘤学杂志》 CAS 2009年第3期181-184,共4页 Journal of International Oncology
关键词 黑色素瘤 疫苗 皮肤癌 免疫性 组织学 治疗 Cancer vaccine Melanoma
  • 相关文献

参考文献15

  • 1Berd D, Sato T, Maguire Jr HC, et al. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol, 2004, 22 (3) :403-415.
  • 2Lotem M, Shiloni E, Pappo I, et al. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer, 2004, 90(4) :773-780.
  • 3Sondak VK, Sabel MS, Mul'e JJ. AUogeneic and autologous melanoma vaccines:where have we been and where are we going? Clin Cancer Res, 2006, 12(7 Pt 2) :2337s-2341s.
  • 4Phan GQ, Touloukian CE, Yang JC, et aL Immunization of patients with metastatic melanoma using both class Ⅰ-and class Ⅱ-restricted pepfides from melanoma-associated antigens. J Immunother, 2003, 26(4) :349-356.
  • 5Slingluff Jr CL, Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a muhiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol , 2004, 22 (22) : 4474 -4485.
  • 6Scheibenbogen C, Schadendorf D, Bechrakis NE, et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer 2003, 104(2) :188-194.
  • 7Di Pucchio T, Pilla L, Capone I, et al. Immunization of stage.Ⅳ melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8^+ T cells and monocyte/dendfitic cell precursors. Cancer Res, 2006, 66 ( 9 ) : 4943- 4951.
  • 8Wong R, Lau R, Chang J, et al. Immune responses to a class Ⅱ helper peptide epitope in patients with stage Ⅲ/Ⅳ resected melanoma. Clin Cancer Res, 2004, 10(15) :5004-5013.
  • 9Rosenberg SA, Yang JC,Restifo NP. Cancer immunotherapy : moving beyond current vaccines. Nat Med, 2004, 10(9) :909-915.
  • 10Rosenberg SA, Yang JC, Sherry RM, et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanomamelanocyte antigen. Hum Gene Ther, 2003, 14 (8) :709-714.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部